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Background: Although associated adverse pregnancy outcomes, no international or Swedish consensus exists that
identifies a cut-off value or what screening method to use for definition of gestational diabetes mellitus. This study
investigates the following: i) guidelines for screening of GDM; ii) background and risk factors for GDM and selection
to OGTT; and iii) pregnancy outcomes in relation to GDM, screening regimes and levels of OGTT 2 hour glucose
values.
Methods: This cross-sectional and population-based study uses data from the Swedish Maternal Health Care
Register (MHCR) (2011 and 2012) combined with guidelines for GDM screening (2011–2012) from each Maternal
Health Care Area (MHCA) in Sweden. The sample consisted of 184,183 women: 88,140 in 2011 and 96,043 in 2012.
Chi-square and two independent samples t-tests were used. Univariate and multivariate logistic regression analyses
were performed.
Results: Four screening regimes of oral glucose tolerance test (OGTT) (75 g of glucose) were used: A) universal
screening with a 2-hour cut-off value of 10.0 mmol/L; B) selective screening with a 2-hour cut-off value of
8.9 mmol/L; C) selective screening with a 2-hour cut-off value of 10.0 mmol/L; and D) selective screening with
a 2-hour cut-off value of 12.2 mmol/L. The highest prevalence of GDM (2.9%) was found with a 2-hour cut-off value
of 8.9 mmol/L when selective screening was applied. Unemployment and low educational level were associated
with an increased risk of GDM. The OR was 4.14 (CI 95%: 3.81-4.50) for GDM in obese women compared to women
with BMI <30 kg/m2. Women with non-Nordic origin presented a more than doubled risk for GDM compared to
women with Nordic origin (OR = 2.24; CI 95%: 2.06-2.43). Increasing OGTT values were associated with increasing
risks of adverse pregnancy outcomes.
Conclusions: There was no consensus regarding screening regimes for GDM from 2011 through 2012 when four
different regimes were applied in Sweden. Increasing levels of OGTT 2-hour glucose values were strongly associated with
adverse pregnancy outcomes. Based on these findings, we suggest that Sweden adopts the recent recommendations of
the International Association of Diabetes and Pregnancy Study Group (IADPSG) concerning the performance of OGTT
and the diagnostic criteria for GDM.* Correspondence: maria.lindqvist@obgyn.umu.se
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Gestational diabetes mellitus (GDM), one of the most
common metabolic disorders complicating pregnancy, is
defined as any degree of glucose intolerance with onset
or first recognition during pregnancy, and that is not
considered manifest diabetes mellitus type 2 [1]. Risk
factors for GDM are family history of diabetes mellitus
type 2 (DM2), previous GDM, macrosomic infant (de-
fined as 4500 grams or more), BMI ≥30 kg/m2 [2], unex-
plained intrauterine fetal death, maternal age ≥35 years,
and immigrant status [3-5]. The results from the Hyper-
glycemia and Adverse Pregnancy Outcome (HAPO)
study show that higher maternal glucose levels are asso-
ciated with increased macrosomia, caesarean sections
and neonatal hypoglycemia [6]. Compared to normogly-
cemic pregnancies, women with GDM are associated
with a seven-fold increased risk of DM2 later in life [7].
Offspring of women with GDM pregnancies have in-
creased risk of obesity, glucose intolerance, and diabetes
mellitus in puberty or early adulthood, all conditions in-
cluded in metabolic syndrome [8,9].
The global prevalence of GDM is 7% (1-14% depend-
ing on diagnostic tests and the population studied) [10].
Applying the diagnostic criteria of the International As-
sociation of Diabetes and Pregnancy Study Group
(IADPSG) and the international multi-centre HAPO has
demonstrated significant variability of prevalences of
GDM among participating countries and even among
participating study centres within the same country [11].
From a global perspective, Sweden is considered a low
risk country for GDM with an annual prevalence of 1 to
2.6% of this pregnancy-related disorder [12,13]. There is,
however, no international consensus regarding how
women should be screened for GDM, whether screening
should be undertaken universally, or whether women
who present risk factors [14] should undergo screening,
i.e. selective screening. This lack of consensus persists
even though it is recognized that adverse pregnancy out-
comes are associated with GDM and a diagnosis of
GDM results in increased medical surveillance for
mother and fetus during pregnancy [15]. Therefore, it is
impossible to estimate the true prevalence of GDM.
In Sweden, there is no national consensus with respect
to GDM screening [16]. The International Association
of Diabetes and Pregnancy Study Group (IADPSG) has
presented recommendations for thresholds of GDM
based on the epidemiological HAPO study [17], and
these recommendations have also been adopted by the
World Health Organization (WHO) [18]. The proposed
criteria for GDM when using a 75-gram oral glucose tol-
erance test (OGTT) include a fasting plasma glucose of
5.1-6.9 mmol/L (92–125 mg/dL) or a 1-hour plasma glu-
cose of 10.0 mmol/L (180 mg/dL) or a 2-hour plasma
glucose of 8.5 mmol/L (153 mg/dL) [17].Antenatal care (ANC) in Sweden is free and currently
organized in 43 different areas called Maternal Health
Care Areas (MHCA) characterized by geographic bound-
aries corresponding mainly to the Swedish counties. A
consultant obstetrician and a consultant midwife are
responsible for the guidelines regarding maternal and
fetal surveillance and medical management within each
MHCA. National guidelines of surveillance during preg-
nancy in antenatal care have been suggested by the profes-
sional associations of obstetricians and midwives [19];
however, local guidelines may differ between MHCA
[16,19]. The overall aim of antenatal care in Sweden is to
achieve “good sexual and reproductive health for the
whole population”, a goal that is similar to the WHO’s
guidelines for sexual and reproductive health. Almost all
pregnant women in Sweden register in Swedish antenatal
care [19].
In the Nordic countries, there is a unique opportunity
to use population-based national registers for research.
Due to these unique personal data registers, data may be
linked, and individuals and families can be identified in
several generations. The national registers are creating
unique possibilities and are a valuable source of informa-
tion and matrix for clinical trials [20]. The Swedish
Maternal Health Care Register (MHCR) is a national
health register, and data have been collected since 1999 by
midwives in antenatal care. The MHCR underwent a
major revision of the included variables between 2007 and
2009, and a new version of the register was launched in
2010. The MHCR is currently monitoring around 85% of
all pregnant women (personal correspondence).
There is an ongoing discussion internationally regard-
ing the diagnostics of GDM. However, suggestions of
lowering cut-off values for GDM diagnosis, the situation
of GDM screening in Sweden has not changed in the
last decade and there are several regimes of screening
available in clinical practice. Hence, there is an oppor-
tunity to study the outcomes of different screening re-
gimes as to add further information to the knowledge of
outcomes in relation to screening regimes.
This study, which includes data on deliveries in Sweden
from January 1st 2011 to December 31st 2012, investigated
the following: i) guidelines for screening of GDM; ii) back-
ground and risk factors for GDM and selection to OGTT;
and iii) pregnancy outcomes in relation to GDM, screen-
ing regimes and levels of OGTT 2 hour glucose values.Methods
This cross-sectional and population-based study uses
data retrieved from the Swedish Maternal Health Care
Register for 2011 and 2012 in combination with local
guidelines for screening of GDM collected from each
MHCA in Sweden.
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births, with data registered in the MHCR between 2011
and 2012 were included in the study. The coverage of
registered deliveries in the MHCR was estimated to be
81% for 2011 and 85% for 2012 (personal correspond-
ence). The following variables retrieved from the MHCR
were included in the study: country of origin, maternal
age, parity, maternal height, maternal weight, body mass
index, smoking, level of education, self-reported health,
number of visits to antenatal care, use of professional in-
terpreter at visits in ANC, treatment for psychological
ill-health during pregnancy, GDM, OGTT, gestational
age, delivery mode, birth weight, small for gestational
age (SGA), appropriate for gestational age (AGA), and
large for gestational age (LGA) [21].
Local guidelines for screening of GDM were collected
from all MHCA in Sweden (n = 43) through an initial e-
mail request between September and October 2012. The
e-mail requesting local guidelines was sent to the con-
sultant midwife in each MHCA. The majority of guide-
lines were collected during the first round. For those
MHCA that did not respond to the first e-mail, the
consultant midwife in each MHCA was contacted by
telephone or by another e-mail. Finally, guidelines for
screening for GDM were collected from all MHCA in
Sweden. Similarities and differences in the guidelines
were compared. All local guidelines for screening GDM
were unchanged during the study period (2011 to 2012).
Selective screening for GDM based on risk factors
Since 1990, Sweden has officially used the recommenda-
tions developed by the European Association for the
Study of Diabetes for screening for GDM. Both universal
and selective screening regimes stipulate a 75-g glucose
load and the two-hour value of the capillary plasma
glucose for the diagnosis. However, there is no national
consensus regarding the threshold for definition of GDM
in Sweden, so it varies among the different MHCA. Pres-
ently, there are two national approaches for screening for
GDM: one universal screening approach where all preg-
nant women are offered an OGTT and one selective
screening approach based on specified risk factors in the
local guideline. The risk factor approach (i.e., selective
screening) is used by approximately 89% of the MHCA in
Sweden (personal communication). The risk factors that
indicate a need for screening for GDM include family
history of diabetes mellitus type 2 (DM2), GDM, macroso-
mic infant (defined as 4500 grams or more) or stillbirth in
previous pregnancy, BMI ≥30 kg/m2, and non-European
nationality. The risk factors during pregnancy indicating
an OGTT are accelerating fetal growth, polyhydramniosis,
and elevated random capillary plasma glucose. Both uni-
versal and selective screening regimes for the diagnostic
procedures stipulate the use of a 75-g glucose load and the2-hour value of the capillary plasma glucose. One-third of
the MHCA also uses fasting glucose as a diagnostic criter-
ion for GDM.
Definitions of background and outcome variables
Maternal age was defined as age at delivery. Parity was
defined as total number of deliveries (including the
index pregnancy in the register). Maternal height (cm),
and maternal weight in early pregnancy (kg) were self-
reported by the pregnant woman. Body mass index
(BMI) was calculated with the formula BMI kg/m2. The
different BMI groups were defined according to WHO’s
definition of BMI: underweight: <18.5 kg/m2; normal
range: 18.5-24.99 kg/m2; overweight: 25–29.99 kg/m2;
obesity class 1: 30–34.99 kg/m2; obesity class 2: 35–
39.99 kg/m2; and obesity class 3: ≥40 kg/m2. Smoking at
three months before pregnancy and at the first antenatal
visit was reported. Level of education was defined as
elementary school, high school, and university. Self-re-
ported health was reported by the woman during early
pregnancy and divided into five categories: very good,
good, either good or poor, poor, and very poor health.
Gestational diabetes mellitus (GDM) was defined as any
degree of glucose intolerance with onset or first recogni-
tion during pregnancy. The cut-off values – 8.9 mmol/L,
10.0 mmol/L, and 12.2 mmol/L – for the diagnosis
of GDM were determined by the MHCA. OGTT (75 g
2-two-hour oral glucose tolerance test) was used to
diagnose GDM in all parts of Sweden. For analysis,
the OGTT glucose values were categorised into two
different sets. The first set of categories was as follows:
<7.5 mmol/L, 7.5-8.8 mmol/L, 8.1-8.9 mmol/L, 9.0-
9.9 mmol/L, 10.0-12.1 mmol/L, and ≥12.2 mmol/L. The
second set used the categories defined by IADPSG,
which define a normal OGTT as a glucose value of
<8.5 mmol/L, GDM (i.e., glucose value) between 8.5
and 11.0 mmol/L, and manifest diabetes mellitus type 2
(i.e., glucose value ≥11.1 mmol/L) [17]. Delivery mode
was reported as either as vaginal non-instrumental, vagi-
nal instrumental, elective caesarean section, or emer-
gency caesarean section. Birth weight was reported in
grams. In calculations of birth weight, the birth weight
of single births were included as well as birth weight of
first child of duplex or triplex pregnancy. Small for
gestational age (SGA), appropriate for gestational age
(AGA), and large for gestational age (LGA) were calcu-
lated using Marsal’s curve [21].
Ethical approval from the Ethical Review Board in
Umeå was granted 2012 (Dno. 2012-407-3IM).
Statistical analysis
Two-independent samples t-tests were used to test dif-
ferences of parametric data, and non-parametric two-
independent samples tests were used to test differences
Lindqvist et al. BMC Pregnancy and Childbirth 2014, 14:185 Page 4 of 12
http://www.biomedcentral.com/1471-2393/14/185of categorical variables. Univariate and multivariate lo-
gistic regression analyses were performed and presented
with odds ratios (OR) and their 95% confidence intervals
(CI) where different models were demonstrated. The
population attributable proportion (PAP) was calculated
for specified exposures using the formula PAP = p(RR-1)/
[1 + p(RR-1)], where PAP is the proportion of cases in the
population that should not have occurred had the exposed
had the incidence of the unexposed. Statistical analysis
was done using SPSS version 19.
Results
The total sample consisted of 184,183 deliveries (88,140
in 2011 and 96,043 in 2012). Mean maternal age and
mean parity at delivery was 30.25 years and 1.8, respect-
ively (Table 1). Table 1 shows the background character-
istics for the whole sample as well as for each year (2011
and 2012). Test of difference was calculated for 2011 vs.
2012 for all variables. The following significant p-values
were found comparing the variables for the year 2011
and the year 2012: maternal age in years (p = 0.032),
weight (0.005), and BMI (p = 0.001). Regarding performed
OGTT, 2011 vs. 2012 significant p-values were found for
the variables weight (p = 0.001), BMI (0.001), educational
level (p = 0.003), employment status (p = 0.012), number of
visits to ANC (p = 0.011), SRH (p = 0.001), reported smok-
ing three months before pregnancy (p = 0.001), and re-
ported smoking at first visit (p = 0.001). The variables are
presented in Table 1.
Four screening regimes for diagnostics of GDM in
Sweden
Nationally, four GDM screening regimes were used be-
tween 2011 and 2012, using different capillary plasma
glucose values for the diagnosis of GDM. Accordingly,
there was no national consensus regarding screening
and diagnosis of GDM in Sweden (Table 2). Four
schemes for GDM screening were followed: A) universal
screening with a 2-hour cut-off value of 10.0 mmol/L;
B) selective screening with a 2-hour cut-off value of
8.9 mmol/L; C) selective screening with a 2-hour cut-off
value of 10.0 mmol/L; and D) selective screening with a
2-hour cut-off value of 12.2 mmol/L. The OGTT 2-hour
cut-off value of 12.2 mmol/L as diagnosis for GDM in
the fourth category was regarded as diagnosis of mani-
fest diabetes mellitus in the majority of the MHCA in
Sweden. Most pregnant women (56.8%) in Sweden
underwent selective screening of GDM with a 2-hour
cut-off glucose value of 10.0 mmol/L. Fewer pregnant
women (11.3%) were offered universal screening with
the same criteria for diagnosis (10 mmol/L). In total,
88.7% of pregnant women in Sweden underwent select-
ive screening. The background factors family history
of diabetes mellitus type 2, previous GDM, macrosomicinfant (≥4.5 kg), and BMI >30 kg/m2 were used by
81% of the MHCA as indicators for OGTT during preg-
nancy. Other indicators were unexplained intrauterine
fetal death, maternal age more than 35 years, and immi-
grant status. Among the MHCA, only four had immigrant
status as an indicator for OGTT. A vast majority of
MHCA (81%) used BMI >30 or 35 as an indicator for
OGTT. The most prevalent risk indicator for OGTT was
elevated random plasma glucose (8.0-9.0 mmol/L), which
was presented in all the MHCA using selective screening.
Prevalences of OGTT and GDM
Table 2 presents maternal background characteristics,
prevalences of OGTT, GDM, and birth weight (mean,
minimum, and maximum) in relation to current regimes
of screening of GDM between 2011 and 2012. As ex-
pected, the prevalence of OGTT was highest (93.6%) in
the MHCA that offered pregnant women universal
screening of GDM, and the prevalence of OGTT was
lowest (6.8%) in the screening category with a 2-hour
cut-off value of 12.2 mmol/L as criteria for GDM
(Table 2). The lowest prevalence of OGTT was for
women younger than 19 years old (17.6%). The highest
prevalence was for women 40 years old or older (24.0%)
(Table 1). As body mass index increased, the prevalence
of OGTT increased. The lowest prevalence was for
women in the lowest BMI category (BMI < 18.5 kg/m2;
13.6%), and the highest prevalence was for women with
a BMI between 35 and 39.99 kg/m2 (65.7%) and women
with BMI 40 or higher (73.3%) (Table 1). The highest
prevalence of GDM (2.9%) was found in the areas where
selective screening was applied with an OGTT 2-hour
value of 8.9 mmol/L as criteria for diagnosis of GDM
(Table 2). As shown in Table 1, the prevalence of GDM
increased with increasing values in categories of mater-
nal age, BMI, and parity. Furthermore, the prevalence of
GDM increased in women who had a low educational
level, who were unemployed, and who rated their health
as “either good or poor” or “very poor” compared to
women with higher educational level, women who were
employed, and women who rated their health as “good
or very good” (Table 1).
Population attributable proportion
To calculate the population attributable proportion,
we selected the two screening regimes universal screen-
ing “A” (Table 2) and selective screening “C” (Table 2)
(i.e., two categories using the same 2-hour capillary
plasma glucose value of 10 mmol/L for diagnosis of
GDM). For each screening regime, the PAP for GDM
was calculated for the exposures obesity, increased ma-
ternal age (i.e., maternal age 35 years or more), and
non-Nordic origin. For the screening regime “A”, 20%,
14%, and 22% of GDM cases could be attributed to











Maternal (yrs) 184130 (99.8) 88016 (99.7) 96025 (99.9) 38302 (99.8) 2579 (99.8)
Mean(SD) 30.25 (5.3) 30.27 (5.3) 30.23 (5.3) 30.36 (5.4) 31.86 (5.5)
Min-Max 13-57 13-53 13-57 15-54 16-53
Maternal age
≤19 2688 (1.5) 1369 (1.6) 1319 (1.4) 469 (17.6) 23 (0.9)
20-24 25212 (13.7) 11990 (13.8) 13222 (13.8) 5293 (21.2) 239 (1.0)
25-29 53971 (29.3) 25570 (29.0) 28393 (29.6) 11257 (21.0) 618 (1.1)
30-34 61706 (33.5) 29463 (33.4) 32243 (33.6) 12432 (20.3) 837 (1.4)
35-39 33225 (18.0) 16215 (18.4) 17010 (17.7) 7130 (21.5) 642 (1.9)
≥40 738 (4.0) 3490 (4.0) 3838 (4.0) 1748 (24.0) 220 (3.0)
Parity 181292 (98.4) 86189 (96.0) 95103 (98.2) 37603(96.8) 2548 (97.3)
1 79250 (43.7) 37569 (43.6) 41681 (43.8) 15493 (19.7) 949 (1.2
2 67902 (37.5) 32340 (37.5) 35562 (37.4) 14130 (20.9) 861 (1.3)
≥3 34140 (18.8) 16280 (18.9) 17860 (18.8) 7980 (22.8) 738 (2.9)
Gest agebc 180822 (98.2) 86434 (97.9) 94388 (98.1) 37684 (97.2) 2513 (97.6)
Pre-term 9838 (5.4) 4689 (5.4) 5149 (5.5) 1914 (19.6) 209 (2.1)
Term 156599 (86.6) 74874 (86.6) 81725 (86.6) 32714 (21.0) 2208 (1.4)
Post-term 14385 (8.0) 6871 (8.0) 7514 (8.0) 3056 (21.4) 96 (0.7)
Weight (kg) 179343 (97.4) 85359 (97.9) 93984 (97.9) 37062 (96.8) 2510 (97.3)
Mean (SD) 68.50 (13.7) 68.40 (13.6) 68.59 (13.7) 75.45 (17.7) 7704 (18.6)
Min-Max 29-183 29-183 30-183 36-183 40-163
Height (cm) 180124 (97.8) 85764 (97.3) 94360 (98.2) 37762 (97.3) 2519 (97.7)
Mean (SD) 166.2 (6.5) 166.2 (6.5) 166.2 (6.5) 166.2 (6.6) 163.8 (6.8)
Min-Max 113-196 113-193 113-196 133-195 133-187
BMI (kg/m2)d 178723 (97.0) 85046 (97.5) 36967 (96.8) 2496(96.8)
Mean (SD) 24.78 (4.6) 24.74 (4.6) 24.82 (4.7) 27.29 (6.1) 28.70 (6.3)
Min-max 13.6-62.6 13.8-62.1 13.6-60.0 13.6-62.1) 16.0-60.0
BMI early pregnancy 178723 (97.0) 85046 (97.5) 93677 (96.7) 36967 (96.5) 2496(96.8)
<18.5 4329 (2.4) 2031 (2.4) 2298 (2.5) 586 (13.6) 23 (0.5)
18.5-24.99 1056679(59.1) 50622(59.5) 55057 (58.8) 15633 (14.9) 789 (0.7)
25-29.99 45667 (25.6) 21641 (25.4) 24026 (25.6) 9285 (20.4) 754 (1.7)
30-34.99 16126 (9.0) 7537 (8.8) 8589 (9.2) 6793 (42.4) 511 (3.2)
35-39.99 5117 (2.9) 2379 (2.8) 2738 (2.9) 3327 (65.7) 285 (5.8)
≥40 1805 (1.0) 836 (1.0) 969 (1.0) 1313 (73.3) 134 (7.4)
Educational level 151600 (82.3) 70638 (79.5) 80962 (84.0) 32183 (82.3) 2003 (76.5)
Elementary school 13532 (8.9) 6662 (9.4) 6870 (8.5) 3239 (24.1) 309 (2.4)
High school 60481 (39.9) 27821 (39.4) 32660 (40.3) 14263 (23.7) 904 (1.5)
University 77587 (51.2) 36155 (51.2) 41432 (51.2) 14681 (19.0) 790 (1.0)
Employment status 179628 (97.5) 85165 (94.6) 94463 (98.0) 37330 (96.1) 2501 (95.6)
Employede 159566 (88.8) 75669 (88.8) 83897 (88.8) 32805 (21.9) 2057 (1.6)
Unemployedf 20062 (11.2) 9496 (11.2) 10566 (11.2) 4525 (22.9) 444 (2.4)
Country of origin 184132 (100) 88140 (100) 96043 (100) 38308 (97.6) 2579 (97.2)
Sweden 144563 (78.5) 70376 (79.8) 74187 (77.2) 29637 (20.6) 1613 (1.1)
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Table 1 Characteristics of subjects and test of difference between specified categories (Continued)
Nordic countriesg 1445 (0.8) 613 (0.7) 832 (0.9) 350 (24.6) 23 (1.7)
Other countries 34134 (18.5) 17151 (19.5) 21024 (21.9) 8318 (22.4) 943 (2.8)
Visits at ANCh 182137 (98.9) 86822 (98.6) 95315 (99.2) 37917(99.0) 2534 (98.3)
Mean: 8.8 (2.4) 8.8 (2.4) 8.7 (2.7) 9.0 (2.4) 9.3 (3.0)
Max-min: 1-29 2-26 1-24 1-29 1-26
SRHi 153227 (83.2) 70633 (79.1) 82594 (85.7) 32442 (83.3) 2102 (80.3)
Very good 44310 (28.9) 19838 (28.1) 24472 (29.6) 8484 (19.2) 422 (1.0)
Good 89740 (58.6) 41299 (58.5) 48441 (58.6) 19650 (22.0) 1317 (1.5)
Either good or poor 13755 (9.0) 6793 (9.6) 6962 (8.4) 3142 (23.0) 260 (1.9)
Poor 4371 (2.9) 2174 (3.1) 2197 (2.7) 950 (21.8) 82 (1.9)
Very poor 1051 (0.7) 529 (0.7) 522 (0.6) 216 (20.7) 21 (2.0)
Smoking 3 monthsj 182532 (99.1) 75316 (98.8) 81797 (99.2) 38305 (97.5) 2579(97.6)
No smoking 157113 (85.2) 75316 (85.5) 81797 (86.1) 31718 (20.3) 2167(1.4)
Smoking 25419 (14.8) 12134 (14.5) 13285 (13.9) 5976 (23.7) 387 (1.6)
Smoking first visit 182619 (99.0) 84134 (94.2) 96043 (98.5) 38305 (97.6) 2579 (97.6)
No smoking 172082 (94.3) 82451 (94.2) 89631 (94.1) 35139 (20.5) 2380 (1.5)
Smoking 10537 (5.7) 5062 (5.7) 5475 (5.9) 2578 (24.6) 174 (1.7)
aFor each specified variable, n and% are presented.
bGestational age calculated using the WHO’s guidelines.
cPre-term = 22 + 0-36 + 6, Term = 37 + 0-41 + 6, Post-term = 42 + 0–43 + 6 (weeks).
dBody mass index (BMI).
eEmployed includes employed, student, and parental leave.
fUnemployed includes unemployed, sick leave, and other.
gNorway, Denmark, Finland, and Iceland.
hAntenatal care unit (ANC).
iSelf-rated health (SRH).
jSmoking three months before pregnancy.
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respectively. The corresponding PAPs for screening re-
gime “C” were 31%, 17%, and 19% of GDM cases that
could be attributed to obesity, increased maternal age,
and non-Nordic origin, respectively.Table 2 Maternal characteristics and specific outcomes in rela
mellitus (GDM) in Sweden between 2011 and 2012
Variables All MAa (yrs) He
n (%) Mean M
Min-max M
A. Universal screening 10.0 mmol/Ld 20822 (11.3) 30.0 16
15–49 14
B. Selective screening 8.9 mmol/Ld 8634 (4.7) 29.8 16
15–49 13
C. Selective screening 10.0 mmol/Ld 104688 (56.8) 29.8 16
13–54 11
D. Selective screening 12.2 mmol/Ld 50039 (27.2) 31.4 16
14–57 12
aMaternal age (MA).
bBody mass index (BMI) kg/m2.
cOral glucose tolerance test (OGTT).
dCut-off value.Maternal characteristics and pregnancy outcomes in
relation to screening regimes
Maternal characteristics and pregnancy outcomes such as
maternal age, maternal BMI, birth weight, large for gesta-
tional age, and small for gestational age are presented intion to four screening regimes for gestational diabetes
ight (cm) BMIb BMIb OGTTc GDM
ean Mean ≥30 n (%) n (%)
in-max Min-max n (%)
6.4 25.04 2784 (14.1) 19294 (93.6) 456 (2.2)
0–190 13.63–55.98
6.4 24.99 1110 (13.4) 1674 (19.6) 252 (2.9)
5–190 13.82–56.65
6.2 25.04 14523 (14.2) 13934 (13.4) 1494 (1.4)
3–195 13.90–62.06
6.2 24.11 4631 (9.6) 3403 (6.8) 377 (0.8)
3–196 13.97–56.40)
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relation to the subcategories of GDM and non-GDM
within each screening regime. The levels of maternal
BMI among non-GDM cases were similar between re-
gimes with the exception of non-GDM cases in the cat-
egory where selective screening with a cut-off value of
12.2 mmol/L was applied, which presented a lower
BMI-value (Table 3). Overall, the highest prevalence of
LGA cases (20.6%) was found among women with
GDM in the MHCA where selective screening and a
2-hour cut-off value of 12.2 mmol/L for diagnosis of
GDM was applied (Table 3).Pregnancy outcomes in relation to OGTT 2-hour glucose
values
Increasing OGTT 2-hour glucose values were associated
with increasing prevalences of adverse pregnancy out-
comes such as instrumental vaginal delivery, caesarean
section (elective CS as well as emergency CS), and large
for gestational age (Table 4). Prevalences of LGA ranged
from 5.7% (OGTT 2-hour glucose value of ≤7.5 mmol/L)
to 15.6% (OGTT 2-hour glucose value ≥12.2 mmol/L).
Prevalences of SGA were fairly similar in the different
categories of OGTT values, ranging from 2.0 to 2.7%
(Table 4). Furthermore, we categorized the OGTT 2-hour
glucose values according to the criteria defined by
IADPSG and WHO. The same pattern as in Table 4 was
seen with increasing prevalences of similar adverse preg-
nancy outcomes (Table 5).Table 3 Maternal characteristics and specified pregnancy out





Universal screening 10.0 mmol/Ld
GDM 31.58 27.63
Non GDM 29.98 24.98
Selective screening 8.9 mmol/Ld
GDM 31.67 28.27
Non GDM 29.72 24.89
Selective screening 10.0 mmol/Ld
GDM 31.71 29.22
Non GDM 29.77 24.98
Selective screening 12.2 mmol/Ld
GDM 32.94 27.98
Non GDM 31.39 24.08
aBody mass index (BMI) kg/m2.
bLarge for gestational age (LGA).
cSmall for gestational age (SGA).
dOGTT 2-hour cut-off value.Gestational diabetes mellitus in relation to maternal
characteristics
Table 6 presents univariate and multivariate logistic re-
gression analyses for the outcome GDM in relation to
non-GDM for different background variables such as
BMI, maternal age, country of origin, employment sta-
tus, and educational level. Among the background vari-
ables investigated, obesity (defined as BMI >30 kg/m2)
demonstrated the strongest impact on risk of GDM
(Table 6). The OR for GDM was 4.14 (95% CI 3.81-4.50)
for women with obesity compared to women with BMI
less than 30. When adjusting for age, country of birth,
employment status, and educational level, the OR was
moderately changed with an OR of 3.66 (95% CI 3.31-
4.01). Women with a non-Nordic origin had more than
twice the risk for GDM in relation to women with Nor-
dic origin (Table 6).
Pregnancy outcomes in relation to gestational diabetes
mellitus
Maternal characteristics and pregnancy outcomes are pre-
sented in Table 3 in relation to the four screening regimes
and the subcategories of GDM and non-GDM within each
screening regime. The maternal BMI was significantly higher
for GDM cases compared to non-GDM cases regardless
of screening regime category. The highest mean BMI was
found for GDM cases exposed to screening regime C
(29.22 kg/m2) (Table 3). The prevalence of LGA was signifi-
cantly higher for GDM cases in all screening regime categor-
ies. In relation to non-GDM cases in each screening regimecomes in relation to categories of universal and selective







Mean n (%) p-value p-value
890 (4.4) 478 (2.4)
3540 46 (10.5) <0.001 17 (3.9) 0.121
3533 844 (4.3) 59 (2.3)
382 (4.7) 218 (2.7)
3567 25 (10.4) <0.001 7 (2.9) 0.588
3555 352 (4.4) 210 (2.6)
4375 (4.3) 2586 (2.5)
3636 215 (14.9) <0.001 19 (1.3) 0.063
3534 4184 (4.1) 2561 (2.5)
1903 (4.0) 1289 (2.7)
3610 84 (20.6) <0.001 14 (3.8) 0.058
3506 1819 (3.9) 1273 (2.7)
Table 4 Oral glucose tolerance test (OGTT) 2-hour values in categories in relation to specified pregnancy outcomes









CSd Elective CS Emergency CS
(mmol/L) n (%) Mean min-max n (%) n (%) Delivery n(%) Delivery n (%) n (%) n (%) n (%)
<7.5 26307 (71.6) 3594 1445 (5.7) 590 (2.4) 20082 (76.5) 1781 (6.8) 4388 (16.7) 1928 (7.3) 2455 (9.3)
300–5890
7.5–8.0 3644 (9.9) 3663 316 (9.0) 68 (2.1) 2646 (72.7) 264 (7.2) 732 (20.1) 302 (8.3) 430 (11.8)
345–5940
8.1–8.9 3576 (9.7) 3682 355 (10.3) 64 (2.0) 2537 (71.1) 262 (7.3) 770 (21.6) 315 (8.8) 455 (12.7)
990–6020
9.01–9.9 1504 (4.1) 3640 177 (12.2) 31 (2.4) 1024 (68.4) 105 (7.0)) 369 (24.1) 157 (10.4) 211 (14.1)
491–6270
10.0–12.1 1411 (3.8) 3620 198 (14.8) 30 (2.5) 917 (65.2) 101 (7.2) 388 (27.6 174 (12.4) 214 (15.4)
512–5955
≥12.20 310 (0.8) 3619 46 (15.6) 7 (2.7) 188 (60.8) 24 (7.8) 97 (31.4) 44 (12.7) 57 (17.8)
1103–5540
aLarge for gestational age (LGA).
bSmall for gestational age (SGA).
cVacuum extraction or forceps.
dCeasarean section (CS).
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screening regimes A and B, more than three times higher
in screening regime C, and five times higher in screening
regime D (Table 3). The highest mean birth weight was
demonstrated for GDM cases in screening regime C
(3636 g) (Table 3). There was a significantly increased risk
of CS delivery in the group of GDM cases compared with
non-GDM cases (OR = 1.90, 95% CI 1.74-2.07). However,
there was no statistically significant difference between
elective CS or emergency CS regarding GDM (p = 0.169).
Large for gestational age in relation to maternal
characteristics
Large for gestational age fetus was strongly related to
maternal obesity (BMI > 30), with an OR of 2.46 andTable 5 Oral glucose tolerance test (OGTT) 2-hour values in c







(mmol/L) n (%) Mean min-max n (%) n (%) Del
<8.5 31974 (87.0) 3605 1940 (6.2) 696 (2.2) 241
300–5964
8.5–11.0 4082 (11.1) 3661 474 (11.8) 76 (1.9) 279
491–6270
≥11.1 696 (1.9) 3646 124 (18.3) 18 (2.7) 433
1103–5955
aLarge for gestational age (LGA).
bSmall for gestational age (SGA).
cVacuum extraction or forceps.
dCeasarean section (CS).95% CI 2.33-2.60. When adjusting for maternal age, the
OR for LGA moderately changed with an OR of 2.44
(95% CI 2.31-2.58). Furthermore, when adjusting for
screening regime category, the OR was only slightly
altered (OR 2.38, 95% CI 2.25-2.54). Non-Nordic origin
demonstrated a protecting effect for LGA (OR 0.75;
95% CI 0.71-0.80).
Discussion
Between 2011 and 2012 there was no national consensus
regarding screening regimes of GDM in Sweden, and
this situation is still prevailing. In this population-based
cross-sectional study, we found that four screening and
diagnostic regimes of GDM were applied in Sweden.





CSd Elective CS Emergency CS
ivery n (%) Delivery n (%) n (%) n (%) n (%)
62 (75.7) 2201 (6.9) 5548 (17.4) 2392 (7.8) 3156 (9.6)
9 (68.8) 285 (11.2) 987 (24.2) 433 (10.6) 554 (13.6)
(62.5) 51 (7.4) 209 (30.2) 95 (11.9) 114 (18.3)
Table 6 Univariate and multivariate logistic regression analysisa b for gestational diabetes mellitus (GDM) in relation to
non-GDM for specified variables between 2011 and 2012








BMIc <30.00 1 1 1 1 1
BMI ≥30.00 4.14 (3.81–4.50) 4.10 (3.74–4.42) 4.00 (3.68–4.35) 3.93 (3.62–4.28) 3.66 (3.31–4.01)
Age <35 1 1 1 1 1
Age ≥35 1.79 (1.15–1.95) 1.72 (1.58–1.87) 1.71 (1.57–1.86) 1.71 (1.57–1.86) 1.60 (1.59–1.93)
Nordic countriesd 1 1 1 1
Non Nordic countries 2.24 (2.06–2.43) 2.18 (2.01–2.37) 2.10 (1.92–2.28) 2.10 (1.87–2.28)
Employede 1 1 1
Unemployedf 1.74 (1.57–1.93) 1.27 (1.14–1.42) 1.20 (1.10–1.36)
University levelg 1 1
<University level 1.62 (1.48–1.77) 1.34 (1.21–1.47)
aCrude odds ratio.
bAdjusted odds ratio and their 95% confidence intervals.
cBody mass index (BMI) kg/m2.
dNorway, Finland, Denmark, and Iceland.
eEmployed includes employed, student, and parental leave.
fUnemployed includes \unemployed, sick leave, and other.
gElementary school/high school.
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prevalence of OGTT was seen in the MHCA that used
selective screening with an OGTT 2-hour cut-off value
of 12.2 mmol/L as criteria for GDM. The highest preva-
lence of GDM (2.9%) was seen in the area where select-
ive screening used an OGTT 2-hour cut-off value of
8.9 mmol/L. Maternal obesity, maternal age more than
35 years, non-Nordic origin, and lower level of education
were all prominent risk factors for GDM. Furthermore,
these background variables constituted risk factors for
LGA except for women with a non-Nordic origin, result-
ing in a decreased risk of LGA. Most pregnant women
in Sweden underwent selective screening of GDM using
different OGTT 2-hour cut-off values for diagnosis. Few
Swedish pregnant women (11.3%) were offered universal
screening for GDM. In the MCHA with the lowest
OGTT 2-hour cut-off value (8.9 mmol/L) as criteria for
diagnosis of GDM, the prevalence of GDM was signifi-
cantly higher (2.9%), compared to areas that used higher
OGTT 2-hour cut-off values (10.0 and 12.2 mmol/L;
2.2% and 0.8%) as criteria for GDM diagnosis.
Sweden is considered to have a rather low prevalence
of GDM (i.e., around 1.4%) [12]. Using the current
screening methods and thresholds in Sweden, this study
confirmed this level of GDM. Clearly, the “true level” of
GDM within a specific setting depends on screening
method (universal/general), the criterion for diagnosis of
GDM [22], coverage of OGTT in the targeted popula-
tion, the OGTT 2-hour cut-off value, and background
characteristics of the pregnant population [23].
The International Association of Diabetes and Pregnancy
Study Group (IADPSG) and WHO suggest the followingdiagnostic criteria and cut-off values for diagnosis of GDM:
a fasting plasma glucose of 5.1 mmol/L (92 mg/dL) or a
1-hour plasma glucose of 10.0 mmol/L (180 mg/dL) or a
2-hour plasma glucose of 8.5 mmol/L (153 mg/dL) [18].
Only a minor part (4.7%) of Swedish pregnant women
were exposed to a screening regime for diagnosing
GDM at a 2-hour plasma glucose of 8.9 mmol/L, which
is higher than the cut-off value of 8.5 mmol/L recom-
mended by IADPSG and WHO [17,18]. Furthermore,
more than one quarter of Swedish women underwent
selective screening regime with a 2-hour plasma glucose
value of 12.2 mmol/L or more, which commonly is
graded as manifest diabetes mellitus. We find this se-
lective screening regime unacceptable. The results in
our study agree with the findings in the HAPO studies,
where increasing 2-hour glucose values are associated
with increasing risks for adverse pregnancy outcomes
[2,6]. In fact, a major part of the world has adopted the
recommended diagnostic criteria presented by IADPSG
and WHO and our suggestion is that Sweden should
follow this trend as well.
The resistance to accepting IADPSG and WHO rec-
ommendation of using the OGTT 2-hour cut-off values
is related to expectations of increased work load for
primary health providers due to the demand of follow-
up by health services and the issue of unproven cost-
effectiveness [24].
In our study, the highest prevalence of LGA (20.6%)
was found in the MHCA where selective screening with
a 2-hour cut-off value of 12.2 mmol/L for GDM diagno-
sis was applied. This high level of LGA differs from
the prevalence of LGA in other MHCA where other
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2-hour cut-off value of 10.0 mml/L (universal screening;
LGA prevalence of 10.5%) and selective screening with a
2-hour cut-off value of 8.9 mml/L (selective screening;
LGA prevalence of 10.4%).
This high level of LGA (20.6%) might be explained by
undiagnosed glucose intolerance with additional non-
exposure to intervention by health care services. This
situation is especially noteworthy since the mean maternal
BMI (24.11 kg/m2) in this GDM screening regime cat-
egory was significantly lower (p-value <0.001) compared
to the mean maternal BMI in the other categories of
GDM screening regimes (Table 3). The non-consensus re-
garding OGTT 2-hour cut-off values for diagnosis of
GDM and the different regimes for screening is consistent
with European protocols as a whole, demonstrating incon-
sistencies in GDM screening practices [23].
As demonstrated by the HAPO studies, there are con-
tinuous associations between maternal glucose levels
and increasing birth weight and prevalence of caesarean
section [6,14,25]. As previously mentioned, our study’s
results agree with these results and demonstrate in-
creased risks of LGA, instrumental vaginal delivery,
and caesarean section in relation to increased levels of
OGTT 2-hour glucose values. Increased maternal age as
a risk factor for GDM has been reported previously
[3,4], and our study confirms this association. Low so-
cioeconomic status as a risk factor for GDM has also
been reported previously [4], a finding also confirmed
by our study. We suggest that older maternal age and
low socioeconomic status should be considered as indi-
cators for performance of OGTT when using a selective
screening approach. Adverse pregnancy outcomes such
as CS are well known as an adverse pregnancy outcome
related to GDM, an association also confirmed by our
study where the prevalence of CS increased with in-
creased OGTT 2-hour glucose values. The OR was 1.92
times higher (95% CI 1.75-2.06) for CS compared to
vaginal delivery for women with GDM compared to preg-
nant women without GDM. The same pattern could be
seen regarding the risk of LGA. Women of non-Nordic
origin presented a significant lower risk for LGA compared
to women of Nordic origin (OR 0.75, 95% CI 0.71-0.80)
and these findings have been reported previously [26].
The OR was 1.79 times higher (95% CI 1.15-1.95) for ma-
ternal age ≥35 years compared to maternal age <35 years.
The importance of including maternal age of 35 years or
more as an indicator for OGTT was supported by the PAPs
values calculated for GDM for the two screening regimes
“A” and “C” (see Results), showing that 14% vs. 17% could
be attributed to maternal age ≥ 35 years.
Obesity is a global epidemic and has become a public
health issue due to its association with complications dur-
ing pregnancy, including significant adverse conditionssuch as preeclampsia, GDM, LGA, stillbirth, and caesar-
ean section [27,28]. In our study, obese women had a
substantial increased risk of GDM (OR 4.14; CI 95%:
3.81-4.50) compared to normal weight women.
Methodological considerations
The internal validity of data included in the Maternal
Health Care Register (MHCR) has been investigated.
Unpublished results have shown an overall high cover-
age of variables and a satisfying quality of a major part
of variables included in the register (personal communi-
cation). Because the coverage in the MHCR is consid-
ered high (81% in 2011 and 85% in 2012; personal
communication), we believe the materials to be represen-
tative of the population of pregnant women in Sweden.
Data on maternal height and maternal weight in the
MHCR are mostly self-reported data (personal communi-
cation). Underreporting of the true maternal weight
(i.e., reporting false lower weight) might have influenced
the results, resulting in an underestimation of the preva-
lence of obesity in the Swedish pregnant population, and
accordingly an underestimation of the associations related
to BMI. However, we do not consider this situation as a
major source of bias.
Ethical considerations
All health national registers in Sweden, including MHCR,
comply with the rules and procedures stated by The
National Board of Health and Welfare in Sweden. Collec-
tion and management of patient data in health systems
and health registers are regulated through the Swedish
Patient Data Law. Participation in MHCR is voluntarily.
Midwives in antenatal care inform pregnant women on
the aims and participation of MHCR using the following
strategies: a) advertisements in the waiting room at the
antenatal clinic, b) written information provided if re-
quested by the pregnant woman, and c) at registration in
antenatal care the pregnant woman receives information
orally from the midwife on how data are documented in
the medical files and in MHCR. In a majority of the
MHCA, a pregnant woman completes a form on health is-
sues before registration in antenatal care. Furthermore,
the eligible participants receive information that all results
will be presented on an aggregated level, so no individual
subject can be identified.
Conclusions
There was no consensus regarding screening regimes for
GDM in Sweden. Increasing levels of OGTT 2-hour glu-
cose values were strongly associated with adverse preg-
nancy outcomes. Applying different screening regimes
and definitions of GDM in Sweden results in different
procedures in clinical management of pregnant women
which contributes to unequal health care. Using 2-hour
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http://www.biomedcentral.com/1471-2393/14/185capillary glucose does not follow international recom-
mendations. We therefore suggest that Sweden adopts
the recent recommendations outlined by IADPSG con-
cerning the performance of OGTT and the diagnostic
criteria for GDM. The results in our study further sup-
port that maternal age ≥35 years of age and educational
level should be regarded as risk indicators for perform-
ance of OGTT during pregnancy.
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